Recombinant VSV Neutralization Assay for SARS-CoV-2 Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serological tests for SARS-CoV-2 do not accurately reflect neutralizing antibody levels, which are crucial for assessing immunity and vaccine efficacy, and existing assays for virus-neutralizing antibodies are inadequate.
Innovation Solution
The use of recombinant vesicular stomatitis virus (VSV) particles with the VSV glycoprotein replaced by a coronavirus spike(S) glycoprotein or its fragment/derivative, particularly from SARS-CoV-2, to determine the presence of neutralizing antibodies through a syncytium formation assay with reporter proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional serological tests are used to detect SARS-CoV-2 antibodies, then the tests can identify antibody presence, but they do not accurately reflect neutralizing antibody levels which are crucial for assessing immunity
Solution Approach 1:
The patent uses recombinant VSV particles that copy the structural and functional features of SARS-CoV-2 spike glycoprotein. These pseudoviruses replicate the viral entry mechanism and receptor interaction (ACE2 binding) without containing the actual SARS-CoV-2 genome, allowing neutralizing antibody detection through functional neutralization assays while maintaining measurement precision and reliability
Solution Approach 2:
The patent introduces recombinant VSV particles as an intermediary system between the sample and the detection method. These particles serve as a proxy that translates neutralizing antibody activity into measurable signals through syncytium formation, enabling accurate assessment of neutralizing antibody levels without direct detection of SARS-CoV-2 antibodies
2Measurement precision
If existing virus-neutralizing antibody assays are used, then some neutralizing activity can be detected, but the assays are inadequate for accurately measuring neutralizing antibody levels
Solution Approach 1:
The patent changes the detection parameter from direct antibody binding to functional neutralization measured through syncytium formation. By using recombinant VSV particles with SARS-CoV-2 spike glycoprotein, the assay measures neutralizing antibody function through cell fusion inhibition, providing precise measurement while managing complexity through standardized protocols
Solution Approach 2:
The patent creates a simplified copy of the viral infection process using recombinant VSV particles. These particles replicate the critical viral entry function (ACE2 binding and membrane fusion) without the complexity of complete viral replication, enabling precise neutralizing antibody measurement through reduced but functionally representative assay systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a potent and efficient method to assess the presence of SARS-CoV-2 neutralizing antibodies, correlating with protective immunity and vaccine efficacy, by measuring reporter signals in a controlled manner.
Implementation Method 1
contacting the recombinant VSV particle with a mixture of Vero-DSP1 cells and Vero-DSP2 cells... the first target cell and the second target cell are capable of fusing with one another when contacted with the recombinant rhabdovirus particle
Data Source
AI summary
The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike(S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.